-
Mashup Score: 18Cohort studies on 71 outcomes among people with atopic eczema in UK primary care data - 1 month(s) ago
Nature Communications – Eczema may be associated with atopic as well as non-atopic diseases. Here the authors studied associations between atopic eczema and 71 subsequent adverse health outcomes in…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase - 3 month(s) ago
Journal of Cancer Research and Clinical Oncology – Double-hit lymphoma (DHL) with c-MYC gene translocation is highly aggressive and has a poor prognosis. In DHL cells, activation-induced cytidine…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60A randomized trial of ibrutinib and R‐GDP prior to stem cell transplant in relapsed diffuse large B‐cell lymphoma - 3 month(s) ago
In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bac…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study - 3 month(s) ago
In this global phase 2 study in patients with relapsed/refractory follicular lymphoma (FL), zandelisib was administered on intermittent dosing to mitigate immune-related adverse events and infections…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Real shame that zandelisib - a PI3K delta inhibitor - has had development terminated. The ph II TIDAL study showed good efficacy and safety in rrFL when used as intermittent dosing (7d on, 21d off). I was a PI and it helped a number of my patients. #lymsm https://t.co/PI2l9MI3ui https://t.co/At1SwSsQWW
-
-
Mashup Score: 36CAR T cell combination therapies to treat cancer - 3 month(s) ago
Chimeric antigen receptor (CAR) T cells are effectively used in certain hematological malignancies, though tumor relapse and limited success in solid tumors persist. Recent efforts focus on developing combination treatments to enhance outcomes and safety. Here, we provide a comprehensive overview of such combinatorial approaches and a consideration of ongoing clinical trials.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11Monocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma - 3 month(s) ago
Combining circulating absolute monocyte count and a 4-gene monocyte signature at leukapheresis predicts PFS of LBCL receiving CAR T cells.Monocytes depleti
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models - 4 month(s) ago
Key PointsCD20/CD3 bispecific antibody enhances the efficacy of CD19–directed CAR T cells.Combination treatment improved survival in the Eμ-TCL-1 mouse mod
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 52
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known about the long-term survivorship after CAR T-cell therapy. METHODS We previously reported the results of 298 patients who were leukapheresed with the intent to receive standard-of-care axi-cel (n = 275 infused) after two or more previous lines of therapy at a median follow-up of 12.9 months. Here, we report extended follow-up of this cohort to a median of 58 months, with a focus on late survivorship events. RESULTS Among axi-cel–infused patients, progression-free survival at 5 years was 29% and overall survival (OS) at 5 years was 40%. The 5-year lymphoma-specific survival was 53% with infrequent late relapses. However, the 5-year nonrelapse mortality (NRM) was 16.2%, with over half of NRM events occurring beyond 2 years. Patients who were 60 years and older had a lower risk of
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 51
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known about the long-term survivorship after CAR T-cell therapy. METHODS We previously reported the results of 298 patients who were leukapheresed with the intent to receive standard-of-care axi-cel (n = 275 infused) after two or more previous lines of therapy at a median follow-up of 12.9 months. Here, we report extended follow-up of this cohort to a median of 58 months, with a focus on late survivorship events. RESULTS Among axi-cel–infused patients, progression-free survival at 5 years was 29% and overall survival (OS) at 5 years was 40%. The 5-year lymphoma-specific survival was 53% with infrequent late relapses. However, the 5-year nonrelapse mortality (NRM) was 16.2%, with over half of NRM events occurring beyond 2 years. Patients who were 60 years and older had a lower risk of
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 14Tectonic tales | Professor Alan Collins; Everchanging Earth part 4 - 5 month(s) ago
Listen to this episode from Wonder, by the Geo Co. on Spotify. From the western Mediterranean to Southeast Asia – join our geological globetrots with Professor Alan Collins as we explore the extraordinary interconnectedness of the earth system. After a few episodes of unpacking why today’s landscapes look the way they do, Alan helps Holly and Anthony peer past the present and deep into the rock archives of earth history. [ Wonder podcast takes on the everchanging Earth. In this miniseries we pull apart the mysteries of tectonics, piece together ancient supercontinents, and visit the far space and time corners of our unique planet. ] find us on Instagram @thegeoco __ Welcome to Wonder, brought to you by the Geo Co. Join Holly Cooke & Dr Anthony Reid in conversation about our beautiful, ancient, and alive earth. We are all about connecting people to planet by exploring the curiosities of our natural world. The Geo Co. connects to you from the traditional country o
Source: open.spotify.comCategories: General Medicine News, Hem/OncsTweet
Interesting. Strong association between eczema and subsequent diagnosis of Hodgkin lymphoma in huge UK primary care dataset. Of course it’s probably that the ‘eczema’ is a symptom of the lymphoma which can precede diagnosis by years sometimes. #lymsm https://t.co/iVPF72TMO6